Guide · Updated 2026
Mounjaro vs. Ozempic
Both are once-weekly injections for type 2 diabetes. Mounjaro is newer, stronger on paper, and slightly harder to get covered. Here's how they compare.
At a glance
| Mounjaro | Ozempic | |
|---|---|---|
| Active ingredient | Tirzepatide (GLP-1 + GIP) | Semaglutide (GLP-1) |
| FDA-approved use | Type 2 diabetes | Type 2 diabetes; CV risk reduction in T2D |
| Max dose | 15 mg / week | 2 mg / week |
| A1c reduction (max dose) | ~2.1–2.4% | ~1.5–1.8% |
| Weight loss (max dose) | ~12–15 kg | ~6–7 kg |
| List price | ~$1,070/mo | ~$970/mo |
SURPASS-2: the head-to-head
SURPASS-2 randomized 1,879 adults with type 2 diabetes to tirzepatide 5, 10, or 15 mg vs. semaglutide 1 mg over 40 weeks. All three tirzepatide doses beat semaglutide on both A1c (−2.01% to −2.30% vs. −1.86%) and weight loss (−7.6 kg to −11.2 kg vs. −5.7 kg). Discontinuations for adverse events were similar across all arms.
Cardiovascular data
Ozempic has established cardiovascular outcomes data (SUSTAIN-6, showing a 26% reduction in major adverse cardiovascular events in T2D patients). Mounjaro's CV outcomes trial (SURPASS-CVOT) reads out in 2025 — until then, Ozempic remains the stronger evidence-based choice for T2D patients with heart disease.
Side effects
Both have similar rates of nausea (15–20%), diarrhea, constipation, and vomiting, mostly during dose escalation. Tirzepatide may cause slightly more nausea at the 10–15 mg doses. Both carry the boxed medullary-thyroid-carcinoma warning and both should be paused for elective surgery.
Cost and insurance
For type 2 diabetes, both are commonly covered by commercial plans and Medicare Part D. Copays with insurance are usually $25–$100/month. Cash prices are within $100 of each other. Manufacturer savings cards (Lilly for Mounjaro, Novo Nordisk for Ozempic) can bring commercially insured copays to $25 for eligible patients but don't apply to government insurance.
What about weight loss?
Neither Mounjaro nor Ozempic is FDA-approved for weight loss. Their weight-loss twins — Zepbound (tirzepatide) and Wegovy (semaglutide) — are. Insurance won't cover Mounjaro or Ozempic for weight loss alone, and off-label prescribing is increasingly restricted by payors.
Which should you ask for?
- T2D + established heart disease: Ozempic has the CV outcomes label.
- T2D + weight-loss priority: Mounjaro delivers more weight loss at every matched dose.
- Cost-sensitive with commercial insurance: Whichever your formulary places on the lowest tier.
- Weight loss without diabetes: Ask for Zepbound or Wegovy — the on-label options.
FAQ
Is Mounjaro better than Ozempic?
For A1c reduction and weight loss, Mounjaro outperformed Ozempic in the SURPASS-2 head-to-head trial. It's a stronger drug on both endpoints.
Which is safer?
Both have very similar safety profiles — mainly GI side effects and the boxed thyroid warning. Neither is clearly safer than the other.
Are they interchangeable?
No. Different molecules, different dose scales, different manufacturers. Switching requires re-titrating from the lowest dose.
Which has stronger cardiovascular evidence?
Ozempic — it has an FDA CV risk reduction label from SUSTAIN-6. Mounjaro's CV outcomes trial reads out in 2025.
Can I get either for weight loss?
Neither is FDA-approved for weight loss. The FDA-approved weight-loss versions are Zepbound (tirzepatide) and Wegovy (semaglutide).
See which providers match your situation
Take a 90-second questionnaire and we'll rank your top 3 telehealth providers by medication, budget, and state availability.
Find My Top 3 MatchesEducational content, not medical advice. Talk to a licensed clinician before starting or changing any medication.